ABOS · Acumen Pharmaceuticals, Inc.
$2.13
-0.04 (-1.84%)
At close · Jul 24
Going-concern doubt
— flagged May 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company expects that its current balance of cash and cash equivalents and marketable securities may not be sufficient to fund its operations for at least 12 months from the date of issuance of these financial statements.”View the 10-Q filed May 12, 2026
Market Cap
$156.73M
Shares
72.23M
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Equity Offering (ATM) Programs
| Program Established | Capacity | Remaining | As of | Runs Through | Source |
|---|---|---|---|---|---|
| 2022-07-01 | $50,000,000 | — | 2026-03-26 | — | 10-K , filed 2026-03-26 |
Key facts
CIK
1576885
CUSIP
00509G209
13F (30d)
10 filings
10 filers
Visit website
Investor relations